Stacey Price | Senior Scientific Manager

Price, Stacey

Stacey manages a team of research assistants to deliver bespoke data and innovative R&D projects to facilitate the Garnett lab's progress. Stacey has considerable technical expertise in both molecular and cell biology along with functional screens in both 2D and 3D models of cancer.

Publications

  • Characterizing Mutational Signatures in Human Cancer Cell Lines Reveals Episodic APOBEC Mutagenesis.

    Petljak M, Alexandrov LB, Brammeld JS, Price S, Wedge DC et al.

    Cell 2019;176;6;1282-1294.e20

  • Systematic identification of genomic markers of drug sensitivity in cancer cells.

    Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur A et al.

    Nature 2012;483;7391;570-5

  • A genetic progression model of Braf(V600E)-induced intestinal tumorigenesis reveals targets for therapeutic intervention.

    Rad R, Cadiñanos J, Rad L, Varela I, Strong A et al.

    Cancer cell 2013;24;1;15-29

  • Characterizing Mutational Signatures in Human Cancer Cell Lines Reveals Episodic APOBEC Mutagenesis.

    Petljak M, Alexandrov LB, Brammeld JS, Price S, Wedge DC et al.

    Cell 2019;176;6;1282-1294.e20

  • A lentiviral vector-based insertional mutagenesis screen identifies mechanisms of resistance to MAPK inhibitors in melanoma.

    Ranzani M, Alifrangis C, Thompson NA, Rust AG, Allahyar A et al.

    Pigment cell & melanoma research 2019;32;2;332-335

  • The Origins and Vulnerabilities of Two Transmissible Cancers in Tasmanian Devils.

    Stammnitz MR, Coorens THH, Gori KC, Hayes D, Fu B et al.

    Cancer cell 2018;33;4;607-619.e15

  • Loss of functional BAP1 augments sensitivity to TRAIL in cancer cells.

    Kolluri KK, Alifrangis C, Kumar N, Ishii Y, Price S et al.

    eLife 2018;7

  • Comprehensive Pharmacogenomic Profiling of Malignant Pleural Mesothelioma Identifies a Subgroup Sensitive to FGFR Inhibition.

    Quispel-Janssen JM, Badhai J, Schunselaar L, Price S, Brammeld J et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2018;24;1;84-94

  • Genomic Determinants of Protein Abundance Variation in Colorectal Cancer Cells.

    Roumeliotis TI, Williams SP, Gonçalves E, Alsinet C, Del Castillo Velasco-Herrera M et al.

    Cell reports 2017;20;9;2201-2214

  • Genome-wide chemical mutagenesis screens allow unbiased saturation of the cancer genome and identification of drug resistance mutations.

    Brammeld JS, Petljak M, Martincorena I, Williams SP, Alonso LG et al.

    Genome research 2017;27;4;613-625

  • Genome-wide generation and systematic phenotyping of knockout mice reveals new roles for many genes.

    White JK, Gerdin AK, Karp NA, Ryder E, Buljan M et al.

    Cell 2013;154;2;452-64

  • A genetic progression model of Braf(V600E)-induced intestinal tumorigenesis reveals targets for therapeutic intervention.

    Rad R, Cadiñanos J, Rad L, Varela I, Strong A et al.

    Cancer cell 2013;24;1;15-29

  • Systematic identification of genomic markers of drug sensitivity in cancer cells.

    Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur A et al.

    Nature 2012;483;7391;570-5

Price, Stacey
Stacey's Timeline
2019

Senior Scientific Manager

2017

Joined Mathew Garnett's Faculty team

2016

Scientific Manager

2014

MSc in Cancer Therapeutics - Distinction

2012

Senior Research Assistant

2010

Joined Ultan Mcdermott's faculty team as an Advanced Research Assistant

2008

Joined Sanger as an Advanced Research Assistant in Team 121

2007

BSc Biochemistry with Hons